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Currently, we utilize vitamins and trace elements formulations that are not prepared speciﬁcally for patients
receiving hematopoietic stem cell transplantation (HSCT), and adequacy of this strategy has not been eval-
uated. We prospectively measured blood level of vitamins and trace elements in 15 patients once per week at
6 time points around the acute phase of allogeneic HSCT. We provided standard nutrition support, including
administration of parenteral nutrition with vitamin and trace elements formulation in case of impairment of
oral intake. Most patients had vitamin B1 deﬁciency from the start of preparative regimens. Vitamin C
deﬁciency was prominent throughout the acute phase of HSCT and this was signiﬁcantly associated with high
inﬂammatory markers, C-reactive protein and ferritin. Remarkable vitamin K overload associated with
administration of parenteral supplementation and ferritin overload caused by repeated transfusions was
observed. Moderate deﬁciency of zinc was at least partially linked to gastrointestinal loss by diarrhea. We
revealed several features of vitamin and trace element status in the acute phase of HSCT and provided a basis
for attempts to improve the nutritional condition in HSCT recipients.
 2014 American Society for Blood and Marrow Transplantation.METHODS AND METHODSINTRODUCTION
Nutrition support is one of the most important aspects of
supportive care involved in hematopoietic stem cell trans-
plantation (HSCT), and comprehensive recommendations for
HSCT procedures have been proposed [1,2]. These recom-
mendations underscore the signiﬁcance of receiving HSCT in
well-nourished conditions and maintaining adequate energy
intake during the course of HSCT, even when oral intake is
impaired. To achieve this end, optimal nutritional composi-
tion and route of administration have been investigated.
However, little attention has been paid to fulﬁllment of
vitamin and trace element requirements in the setting of
HSCT thus far.
Currently, adult parenteral multivitamin formulation re-
quirements are based on recommendations proposed in a
workshop sponsored by the Food and Drug Administration
and the American Medical Association in 1985. Similarly, the
American Medical Association proposed the recommenda-
tion of trace elements in adult parenteral nutrition, and
several modiﬁcations were made by American Society of
Parenteral and Enteral Nutrition [3]. In the ﬁeld of HSCT,
these formulations are widely applied in nutritional man-
agement when oral intake is severely impaired. However,
appropriateness of these formulations during the highly
stressful and hypercatabolic state of HSCT has not been
evaluated before. Therefore, we planned this prospective
observational study in which we evaluated the blood level of
these substances in patients during the acute phase of allo-
geneic HSCT.edgments on page 433.
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The subjects were 15 adult patients who received allogeneic HSCT
consecutively at The University of Tokyo Hospital, Japan, between October
2010 and July 2012. The basic characteristics of the patients are shown in
Table 1. This study was performed in accordance with the Helsinki Decla-
ration and approved by the Ethics Committee of The University of Tokyo
Hospital. We obtained written informed consent from all patients.
Stem Cell Transplantation Procedure
Eight patients received myeloablative conditioning regimens and the
other 7 received nonmyeloablative conditioning regimens. Graft-versus-
host disease prophylaxis was performed with calcineurin inhibitors with
short-term methotrexate. Infection prophylaxis was performed with qui-
nolone, azole, and acyclovir.
We routinely consult with nutrition experts and follow their advice. In
most cases, we use a high-calorie total parenteral nutrition solution kit,
which contains glucose, electrolytes, amino acids, vitamins, and trace ele-
ments. In cases of speciﬁc conditions, such as renal damage, we assemble
appropriate nutrition components, including multivitamin preparation and
trace element supplementation.
Measurements of Vitamins and Trace Elements
Vitamins (vitamin B1, vitamin B6, vitamin C, vitamin E, vitamin K, and
folate) and trace elements (iron, zinc, copper, and selenium) were measured
before conditioning regimens (before HSCT), at the day of stem cell infusion
(day 0), and 4 times weekly post transplantation (day 7, day 14, day 21, and
day 28). Alterations of the timing, plus or minus 2 days, were allowed. Pe-
ripheral blood was processed adequately for measurement; eg, protein-free
blood serum was prepared for vitamin C measurement, whole blood with
EDTA-2Na for vitamin B1, and citrate-added plasma for vitamin K series. All
the other items were measured with chilled or frozen plasma. These sub-
stances were measured at SRL, Inc. Japan.
Measurements of Nutrition Status
Oral and total calorie intake were recorded. Basal energy expenditure
(BEE) was calculated with Harris-Benedict equations. Supplementation of
parenteral vitamins and trace microelements was also recorded.
Statistical Analysis
Numerical variables were compared with Student t-test. Correlation
between vitamin C and inﬂammatory proteins (C-reactive protein and
ferritin) were assessed with Spearman’s rank correlation test. A P value
greater than .05 was considered signiﬁcant. Analyses were computed with
R version 2.15.1 (R Foundation for Statistical Computing, Vienna, Austria).
Table 1
Characteristics of the Patients and HSCT
Characteristic n
Sex: male/female 9/6
Age, median (range), yr 48 (34-69)
Disease
Acute myeloid leukemia 7
Myelodysplastic syndrome 2
Non-Hodgkin lymphoma 2
Myeloﬁbrosis 2
Acute lymphoblastic leukemia 1
Chronic myeloid leukemia 1
Disease status
Complete remission 4
Chronic phase 1
Refractory 5
Primary 5
Donor source
uBMT 10
CBT 3
rPBSCT 2
Conditioning
CY/TBI 7
CY/VP16/TBI 1
Flu/Mel/TBI 5
Flu/Bu/TBI 2
BEE, median (range), Kcal 1410 (1055-1654)
HSCT indicates hematopoietic stem cell transplantation; uBMT, unrelated
bone marrow transplantation; CBT, cord blood transplantation; rPBSCT,
related peripheral blood stem cell transplantation; CY, cyclophosphamide;
VP16, etoposide; TBI, total body irradiation, Flu, ﬂudarabine; Mel,
melphalan; Bu, busulfan; BEE, basal energy expenditure.
Data presented are n unless otherwise indicated.
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Study Accomplishments
One patient died of severe sepsis on day 11 and another
refused to provide blood samples on day 21 and day 28. In
the analyses, these 2 patients with incomplete data are
included.Total Calorie Intake and Supplementation Status of
Vitamins and Microelements
Oral intake was impaired in all the patients and dipped
around day 14, when average oral calorie intake was only
122 Kcal/day (354 Kcal/day), although this value was
1563 Kcal/day (654 Kcal/day) before conditioning regimens
started. The oral and parenteral energy intake proﬁle is
demonstrated in Supplementary Figure 1A and the ratio of
total energy intake to BEE is shown in Supplementary
Figure 1B. In 92% of the gross examination points, patients
had either oral calorie intake more than 500 Kcal/day or
parenteral multivitamin preparations (Supplementary
Figure 1C). Also, in 82% of the gross examination points, pa-
tients had either oral calorie intake more than 500 Kcal/day
or parenteral trace elements preparations (Supplementary
Figure 1D).Proﬁles of Vitamins and Microelements
Vitamin B
The normal range of vitamin B1 is from 20 to 50 ng/mL.
Characteristic to the vitamin B1 proﬁle was that average
level was around the normal lower limit before the start of
conditioning (20  4.9 ng/mL). Then, vitamin B1 level
became deﬁcient at day 0 (17.4  4.5 ng/mL) and day 7
(17.8  3.1 ng/mL). Fourteen of 15 samples at day 0 and all 15
samples at day 7 were below the lower normal limit.
Although average levels rose to the normal range at day 21(25  15 ng/mL) and day 28 (28  18 ng/mL), these averages
were pulled up by 1 exceptionally high value at each point
andmany of the samples (10 of 13 samples at day 21, and 9 of
13 samples at day 28) remained below the lower limit level
(Figure 1A).
Vitamin B6
Among the 3 components (pyridoxal, pyridoxine, and
pyridoxamine) that constitute vitamin B6 compounds, we
evaluated pyridoxal value as a representative of vitamin B6.
Overdose was not seen at any evaluation point (Figure 1B).
Vitamin C
The vitamin C proﬁle was salient in its deﬁciency in the
acute phase (Figure 1C). Although the pre-HSCT level of
vitamin C (6.5 4.2 mg/mL) was within the normal range (5.5
to 16.8 mg/mL), a marked deﬁciency was seen from day
0 (3.8 2.6 mg/mL) to all the following measurement periods
and hit the lowest point at day 14 (2.11.4 mg/mL). Vitamin C
levels were inversely correlated with C-reactive protein
values at day 14 (P ¼ .020, r ¼ .61), day 21 (P ¼ .0046,
r ¼ .73), and day 28 (P ¼ .026, r ¼ .61). Similarly, vitamin
C levels showed an inverse correlation with ferritin levels at
day 7 (P ¼ .029, r ¼ .57), day 14 (P ¼ .0046, r ¼ .73), and
day 28 (P ¼ .0011, r ¼ .80) (Supplementary Figure 2).
Vitamin E
The vitamin E level is assumed normal when its value is
.75 to 1.41 mg/dL. Contrary to the previous report that sug-
gested vitamin E deﬁciency in the HSCT setting [4], our pa-
tients showed almost normal vitamin E levels throughout
the acute phase (Figure 1D). This implies that the current
supplementation strategy is well functioning, even under
stressful conditions [5]. Although vitamin E is one of the
most important antioxidant vitamins, vitamin E levels had
no correlationwith inﬂammatory markers at any time points
during HSCT (data not shown).
Vitamin K
Before HSCT, all patients except 1 had a normal vitamin K
level (.15 to 1.25 ng/mL). However, most patients showed
an increase of vitamin K afterwards up to 10 times the normal
upper limit at day 14 (13 5.8 ng/mL) and day 21 (1616 ng/
mL) (Figure 1E). This increasewas apparently associatedwith
start of parenteral nutrition, because the vitamin levels with
and without multivitamin formulation were signiﬁcantly
different (1.5 3.6 ng/mL and 15.613.6 ng/mL, P< .0001 by
t-test) (Supplementary Figure 3).
Folate
Average levels of folate were within the normal range
(>3.1 ng/mL) at all study points. However, median levels
were below the lower normal limit before HSCT (2.9 ng/mL)
and on day 0 (2.9 ng/mL), which reﬂects that more than one
half of the patients had insufﬁcient levels (Figure 1F). Para-
doxically, folate deﬁciency ratio dropped to 21% at day14,
when parenteral nutrition with adequate folate supplemen-
tation was started in most patients.
Ferritin
The ferritin normal range is 3.6 to 340 ng/mL. The serum
ferritin proﬁle and its impact on HSCT outcomes have been
studied extensively by us and others [6]. Ferritin levels
substantially and constantly exceeded the normal rangewith
an increasing trend (Figure 1G).
Figure 1. Serial proﬁles of vitamins and trace elements. Average level of each substance is shown for each time point with SD. Gray zone indicates normal range.
(A) vitamin B1, (B) vitamin B6, (C) vitamin C, (D) vitamin E, (E) vitamin K, (F) folate, (G) ferritin, (H) iron, (I) zinc, (J) copper, and (K) selenium. Study time points are
indicated as follows: pre, before start of conditioning regimens; D0, day of stem cell infusion; D7, day 7 after HSCT; D14, day 14 after HSCT; D21, day 21 after HSCT; and
D28, day 28 after HSCT.
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Serum iron was almost constantly within normal limits
(54 to 200 mg/dL), except for day 0, when the average level
exceeded the normal range slightly (210  44 mg/dL)
(Figure 1H).
Zinc
The normal zinc level is 65 to 110 mg/dL. The average zinc
level went around the lower normal limit during the study
period and fell below this limit at day 14 (60  19 mg/dL) and
day 21 (63  21 mg/dL) (Figure 1I).
Copper
The normal range of copper is 68 to 128 mg/dL. Copper
levels remained within normal limits before conditioning, at
day 0, and day 7; then, the average exceeded the normal upper
level at day 14 (142  23 mg/dL), day 21 (140  26 mg/dL), and
day 28 (144  28 mg/dL). A steady upward trend of this sub-
stance was seen in most of the patients through day 0 to day
14 (Figure 1J).
Selenium
The normal range is not deﬁned for this element, so we
tentatively set 8.0 to 16.0 mg/dL as the normal range because
a selenium concentration above 8.0 mg/dL is associated with
appropriate activities of selenoproteins [7] and 16.0 mg/dL is
the threshold for attention [8]. Selenium deﬁciency is of
great concern in the context of allogeneic HSCT because
there are no parenteral nutrition formulations available in
Japan that contain selenium, whilst selenium is required in
critically ill patients. Our measurements revealed that sele-
nium levels remained in the normal range throughout the
study period (Figure 1K).DISCUSSION
This is the ﬁrst study that evaluated the sufﬁciency of
vitamins and trace elements level during the acute phase of
HSCT. Our study revealed several ﬁndings that were featured
in this population.
One of these features was the shortage of several
substances before the start of conditioning regimens. The
most plausible reason for vitamin B1 deﬁciency would be
the intensive chemotherapies and concomitant appetite
loss that preceded HSCT. However, there was no difference
in the pre-HSCT vitamin B1 level between heavily pre-
treated patients (n ¼ 10) and intensive chemo-
therapyenaïve patients (n ¼ 5, 2 with myelodysplastic
syndrome, 2 with myeloﬁbrosis, and 1 with mycosis fun-
goides) (20.7  5.4 ng/mL and 18.6  4.1 ng/mL, P ¼ .46
by t-test). Actually, none of the chemotherapy-naïve pa-
tients had an adequate vitamin B1 level. The reason for
the deﬁciency in chemotherapy-naïve patients is not clear;
however, excessive demand of vitamin B1 due to
increased energy consumption by malignancy would ac-
count for it. This result indicates that patients should be
surveyed for vitamin B1 level before HSCT and prepared,
irrespective of history of intensive chemotherapies. Folate
also exhibited deﬁciency in more than one half of the
patients before the start of conditioning regimens.
Although alcohol addiction is the major cause of folate
shortage in the general population, this is unlikely for
HSCT recipients. Instead, impaired metabolism by taking
medications, which inhibit dihydrofolate reductase, such
as methotrexate or trimethoprim, may have contributed to
this deﬁciency. Increased consumption of folate by ma-
lignancy may also have been responsible.
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prominent and this shortage was associated with systemic
inﬂammation. This decline is assumed to be attributable to
antioxidant consumption, which is often seen in critically ill
patients [9]. Active supplementation of vitamin C has been
tested with success in distinct conditions, such as in the
perioperative state, in a critically ill condition, and with
major trauma [10]. Therefore, administering megadose sup-
plementation of vitamin C for HSCT recipients would be a
tempting approach.
Because abnormal zinc loss is seen in patients with diar-
rhea and without oral intake [11], the daily zinc requirement
is set at 2.5 mg/day for patients without diarrhea, although
an additional 12 mg should be added for each liter of diar-
rhea [12]. Although diarrhea is a common complication of
HSCT, this modiﬁcation of zinc supplementation is not usu-
ally executed. Actually, at day 28, our patients with diarrhea
had lower zinc levels compared with those without
(61  18 mg/dL and 82  23 mg/dL, P ¼ .048 by t-test)
(Supplementary Figure 4). This correlation was not seen at
earlier time points, probably because most patients suffered
from diarrhea at these points. We should examine the
adequateness of diarrhea-guided zinc replenishment. In
contrast, diarrhea had no impact on the copper level,
although copper is another element that is lost excessively in
diarrhea [13] (data not shown). We assumed that copper is
stored in the human body because its shortage is seen only
after long-standing malabsorption, such as celiac disease or
gastric and small bowel resections [14]. Cholestasis also acts
on the copper level by blocking excretion [15]; however,
there were no correlations between total bilirubin and cop-
per level (data not shown). The plasma copper level should
be interpreted with caution because a standard method to
evaluate body copper status has not been established.
Striking excess of several factors was observed in this
study. Ironwas one of such factors. Ferritin was substantially
high in our patients, and a negative impact of iron overload
has been repeatedly documented thus far [6]. This raises the
issue of adequacy of iron in standard trace elements
formulation. However, an overwhelmingly larger amount of
iron content in RBC transfusions (100 mg in 1 unit in Japan or
in .5 unit in Western countries) makes iron intake in daily
trace element formulations almost negligible. Vitamin K
excess was also remarkable. However, a clinical impact of
excess of vitamin K has not been clearly demonstrated. Rare
cases of vitamin K toxicity were attributed to vehicles of
solubilization [16]. Therefore, considering the severe conse-
quences caused by its deﬁciency, removal of vitamin K from
multivitamin formulation would not be justiﬁed.
Our study is limited by the small number of patients and
various patient backgrounds. Therefore, conﬁrming our
ﬁndings with a larger number of subjects is warranted, and
detailed analyses, including the impact of precedent che-
motherapies and preparative regimens, should be per-
formed. Next, it is necessary to examine the clinical effects of
these aberrations in the context of HSCT. Then, we should
study if speciﬁc nutrition intervention can correct these ab-
errations and ameliorate the subsequent adverse effects.
Ultimately, our ﬁnal goal is the establishment of speciﬁc
formulations optimized for HSCT recipients. However, it is
easily predicted that the variation of patients’ conditions and
HSCT procedures may preclude the development of a uni-
form formulation that is universally applicable. Rather, ad-
justments according to these variations would be realistic. To
this end, it would be helpful to utilize clinical features thatwork as indicators of needed modiﬁcations, because routine
measurements of vitamins and trace elements are imprac-
tical. From our analyses, modiﬁcations are suggested in the
following situations: add vitamin C for patients with severe
inﬂammation and add zinc for patients with diarrhea.
Lastly, because this study aimed to evaluate the adequacy
level of these substances in usual courses of allogeneic HSCT,
nutrition support procedures conformed to clinical practice
in our institution and were not speciﬁcally deﬁned for this
study. Retrospective analysis of energy intake of our patients
revealed slight shortage of energy replenishments because
actual energy intake was around 1.0  BEE (Supplementary
Figure 1B), whereas 1.3 to 1.5  BEE is recommended in
HSCT settings [1]. Additionally, vitamins and trace elements
were not completely reﬁlled when oral intake was impaired
(Supplementary Figure 1C,D). In principle, we follow the
expert nutritionists’ advice to keep total energy amount in
1.3 to 1.5  BEE; however, these shortages arise for several
reasons, including the time gap between recognition of oral
intake decrease and amendments of parenteral pre-
scriptions, patients’ conditions that required ﬂuid load re-
strictions, and catheter removal to manage infections.
Therefore, these results highlight the difﬁculty in adhering to
the recommended care in the presence of varying
restrictions.
In conclusion, we revealed several features of nutrient
adequacy of vitamins and trace elements in patients who
receive allogeneic HSCT. Our results provide a basis for
further attempts to improve HSCT outcomes from the
standpoint of nutrition fulﬁllment.
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